INOSIPLEX: AN IMMUNOMODULATION MODEL FOR THE TREATMENT OF VIRAL DISEASE

T. Ginsberg,A. Glasky

DOI: https://doi.org/10.1111/j.1749-6632.1977.tb21944.x

IF: 6.499

1977-05-01

Annals of the New York Academy of Sciences

Abstract:Despite the enormous expansion of knowledge about viruses and the pathological processes associated with viral infections, the vast array of natural and synthetic substances prepared, extracted, or synthesized to combat viruses continues to be of limited usefulness in human diseases. With the advances in tissue culture techniques, it became relatively convenient to rapidly screen thousands of materials for potential effectiveness in viral diseases in man. Conceiving of a tissue culture system as both a target tissue for application of a drug and the focus of virus infection, investigators were able to observe both viral inhibitory properties and toxicity simultaneously, in addition to obtaining information about intracellular penetration, metabolic reactions, and other factors of importance in the design of potentially useful substances. Animal models could then be of further aid in evaluating the effectiveness and toxicity of potential drug candidates. Thus having passed the necessary criteria in a number of such screening systems, a substance was considered ready for clinical testing. The results in man, unfortunately, have not lived up to our expectations, and there has been little confirmation in humans of the efficacy observed in tissue culture and animal test systems. Today, it is becoming increasingly evident that a delicate balance exists between the invading virus and the natural defenqes of the host. Cell-mediated immunity (CMI) responses are now considered to be of primary importance in these defense mechanisms. A therapeutic agent intende: to retard viral replication processes must act in concert with these defenses, p w y a b l y to augment their effectiveness. It appears, however, that the tissues respo e for cellular immunity, namely those of the lymphoid system, may be among tt most sensitive to the toxicity and suppressive action of prospective antiviral agents.2 To compound the problem, the infectious virus is itself often an inhibitor of the immune response.a Thus, the final result of the intended antiviral therapy may be a tipping of the balance against host defenses and in favor of the virus. I t might therefore be said that a therapeutic drug for treatment of virus infections should minimally have little or no untoward effect on lymphoid functions, and ideally, should augment these functions, Inosiplex (Isoprinosinb), the 3: 1 molar complex of N-N-dimethylamino-2-propanol p-acetamidobenzoate and inosine (FIGURE I ) has been under study as an antivira! agent for several years. The early preclinical and clinical research on inosiplex did not take into consideration the interactions of the drug with elements of the host’s immune response. Nevertheless, we did become aware of such interactions not through problems with lymphotoxicity or lack of effectiveness per se, but through a number of then unexplainable observations that ultimately led to our current concept of the mode of action of the drug. This paper will present a review of some of the important findings that suggested an association between the action of inosiplex and the immune system and lead to the hypothesis that the major factor responsible for the clinical effectiveness of inosiplex is its role as an immunopotentiator.